BioSpace News Archive

BD, a leading global medical technology company, announced that Rishi Grover has been named executive vice president and chief integrated supply chain officer for BD, effective July 7, 2022.

Exelixis, Inc. announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022.

Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL).

Smart Pills market analysis report is produced in such a way that it works toward making the reports easier to read, and easier for managers to absorb the information they need to make decisions.

Healthcare Integration Solutions Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Healthcare Integration Solutions market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Respiratory Care Devices Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Respiratory Care Devices market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi’s pipeline for Greater China.

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for Coronavirus Disease 2019 (COVID-19), has been filed to the U.S. Food and Drug Administration (FDA) after the Pre-IND consultation.

BioArctic AB’s partner Eisai announced that the U.S. Food and Drug Administration has accepted the Biologics License Application under the accelerated approval pathway for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD, with confirmed presence of amyloid pathology in the brain.